A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ISIS 546254 for Preventive Treatment of Chronic Migraine
Phase of Trial: Phase II
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs IONIS PKKRx (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- 29 Apr 2019 Status changed from active, no longer recruiting to completed.
- 02 Apr 2019 Planned End Date changed from 31 Dec 2018 to 30 Jun 2019.
- 02 Apr 2019 Planned primary completion date changed from 31 Dec 2018 to 30 Jun 2019.